Annual EBITDA
-$176.14 M
-$109.73 M-165.22%
December 31, 2024
Summary
- As of March 10, 2025, OCUL annual EBITDA is -$176.14 million, with the most recent change of -$109.73 million (-165.22%) on December 31, 2024.
- During the last 3 years, OCUL annual EBITDA has fallen by -$178.68 million (-7037.50%).
- OCUL annual EBITDA is now -7037.50% below its all-time high of $2.54 million, reached on December 31, 2021.
Performance
OCUL EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$44.33 M
-$12.02 M-37.21%
December 31, 2024
Summary
- As of March 10, 2025, OCUL quarterly EBITDA is -$44.33 million, with the most recent change of -$12.02 million (-37.21%) on December 31, 2024.
- Over the past year, OCUL quarterly EBITDA has stayed the same.
- OCUL quarterly EBITDA is now -914.01% below its all-time high of $5.45 million, reached on March 31, 2021.
Performance
OCUL Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$176.14 M
-$20.22 M-12.97%
December 31, 2024
Summary
- As of March 10, 2025, OCUL TTM EBITDA is -$176.14 million, with the most recent change of -$20.22 million (-12.97%) on December 31, 2024.
- Over the past year, OCUL TTM EBITDA has stayed the same.
- OCUL TTM EBITDA is now -7034.76% below its all-time high of $2.54 million, reached on December 31, 2021.
Performance
OCUL TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
OCUL EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -165.2% | 0.0% | 0.0% |
| 3 y3 years | -7037.5% | 0.0% | 0.0% |
| 5 y5 years | -126.6% | 0.0% | 0.0% |
OCUL EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -7037.5% | at low | -1266.6% | +26.0% | -7034.8% | at low |
| 5 y | 5-year | -7037.5% | at low | -914.0% | +46.7% | -7034.8% | at low |
| alltime | all time | -7037.5% | at low | -914.0% | +46.7% | -7034.8% | at low |
Ocular Therapeutix EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$176.14 M(+165.2%) | -$44.33 M(+37.2%) | -$176.14 M(+13.0%) |
| Sep 2024 | - | -$32.31 M(-18.5%) | -$155.92 M(+30.1%) |
| Jun 2024 | - | -$39.63 M(-33.8%) | -$119.81 M(+22.0%) |
| Mar 2024 | - | -$59.88 M(+148.3%) | -$98.23 M(+47.9%) |
| Dec 2023 | -$66.42 M(+7.3%) | -$24.11 M(-734.5%) | -$66.42 M(+19.6%) |
| Sep 2023 | - | $3.80 M(-121.1%) | -$55.51 M(-31.6%) |
| Jun 2023 | - | -$18.04 M(-35.7%) | -$81.19 M(+1.9%) |
| Mar 2023 | - | -$28.07 M(+112.6%) | -$79.67 M(+28.7%) |
| Dec 2022 | -$61.91 M(-2538.2%) | -$13.20 M(-39.7%) | -$61.91 M(+23.1%) |
| Sep 2022 | - | -$21.88 M(+32.5%) | -$50.30 M(+114.0%) |
| Jun 2022 | - | -$16.52 M(+60.3%) | -$23.51 M(+78.0%) |
| Mar 2022 | - | -$10.30 M(+543.9%) | -$13.21 M(-620.0%) |
| Dec 2021 | $2.54 M(-101.7%) | -$1.60 M(-132.6%) | $2.54 M(-103.2%) |
| Sep 2021 | - | $4.91 M(-179.0%) | -$79.08 M(-15.5%) |
| Jun 2021 | - | -$6.21 M(-214.1%) | -$93.55 M(-23.0%) |
| Mar 2021 | - | $5.45 M(-106.5%) | -$121.50 M(-16.8%) |
| Dec 2020 | -$146.09 M(+87.9%) | -$83.22 M(+770.1%) | -$146.09 M(+69.1%) |
| Sep 2020 | - | -$9.56 M(-72.0%) | -$86.41 M(-7.7%) |
| Jun 2020 | - | -$34.17 M(+78.5%) | -$93.64 M(+14.8%) |
| Mar 2020 | - | -$19.14 M(-18.7%) | -$81.56 M(+4.9%) |
| Dec 2019 | -$77.74 M(+38.9%) | -$23.54 M(+40.2%) | -$77.74 M(+10.0%) |
| Sep 2019 | - | -$16.79 M(-24.0%) | -$70.65 M(+4.1%) |
| Jun 2019 | - | -$22.09 M(+44.1%) | -$67.87 M(+15.9%) |
| Mar 2019 | - | -$15.33 M(-6.8%) | -$58.57 M(+4.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | -$55.95 M(-6.5%) | -$16.44 M(+17.3%) | -$55.95 M(+8.4%) |
| Sep 2018 | - | -$14.01 M(+9.6%) | -$51.59 M(-1.1%) |
| Jun 2018 | - | -$12.78 M(+0.5%) | -$52.17 M(-8.9%) |
| Mar 2018 | - | -$12.71 M(+5.2%) | -$57.26 M(-4.4%) |
| Dec 2017 | -$59.87 M(+42.1%) | -$12.08 M(-17.2%) | -$59.87 M(-0.1%) |
| Sep 2017 | - | -$14.59 M(-18.3%) | -$59.94 M(+10.4%) |
| Jun 2017 | - | -$17.87 M(+16.7%) | -$54.30 M(+14.9%) |
| Mar 2017 | - | -$15.32 M(+26.1%) | -$47.24 M(+12.1%) |
| Dec 2016 | -$42.14 M(+13.1%) | -$12.15 M(+35.7%) | -$42.14 M(+5.3%) |
| Sep 2016 | - | -$8.95 M(-17.2%) | -$40.02 M(-4.7%) |
| Jun 2016 | - | -$10.82 M(+5.9%) | -$41.99 M(+3.5%) |
| Mar 2016 | - | -$10.22 M(+1.9%) | -$40.59 M(+8.9%) |
| Dec 2015 | -$37.27 M(+38.1%) | -$10.03 M(-8.2%) | -$37.27 M(+7.6%) |
| Sep 2015 | - | -$10.92 M(+16.0%) | -$34.62 M(+13.7%) |
| Jun 2015 | - | -$9.42 M(+36.5%) | -$30.44 M(+12.7%) |
| Mar 2015 | - | -$6.90 M(-6.5%) | -$27.01 M(+0.1%) |
| Dec 2014 | -$26.98 M(+116.3%) | -$7.38 M(+9.5%) | -$26.98 M(+17.9%) |
| Sep 2014 | - | -$6.74 M(+12.7%) | -$22.89 M(+17.5%) |
| Jun 2014 | - | -$5.98 M(-12.9%) | -$19.48 M(+18.9%) |
| Mar 2014 | - | -$6.87 M(+108.9%) | -$16.39 M(+31.4%) |
| Dec 2013 | -$12.47 M(-6.3%) | -$3.29 M(-1.4%) | -$12.47 M(+35.8%) |
| Sep 2013 | - | -$3.34 M(+15.5%) | -$9.18 M(+57.1%) |
| Jun 2013 | - | -$2.89 M(-2.3%) | -$5.85 M(+97.7%) |
| Mar 2013 | - | -$2.96 M | -$2.96 M |
| Dec 2012 | -$13.31 M | - | - |
FAQ
- What is Ocular Therapeutix annual EBITDA?
- What is the all time high annual EBITDA for Ocular Therapeutix?
- What is Ocular Therapeutix annual EBITDA year-on-year change?
- What is Ocular Therapeutix quarterly EBITDA?
- What is the all time high quarterly EBITDA for Ocular Therapeutix?
- What is Ocular Therapeutix quarterly EBITDA year-on-year change?
- What is Ocular Therapeutix TTM EBITDA?
- What is the all time high TTM EBITDA for Ocular Therapeutix?
- What is Ocular Therapeutix TTM EBITDA year-on-year change?
What is Ocular Therapeutix annual EBITDA?
The current annual EBITDA of OCUL is -$176.14 M
What is the all time high annual EBITDA for Ocular Therapeutix?
Ocular Therapeutix all-time high annual EBITDA is $2.54 M
What is Ocular Therapeutix annual EBITDA year-on-year change?
Over the past year, OCUL annual EBITDA has changed by -$109.73 M (-165.22%)
What is Ocular Therapeutix quarterly EBITDA?
The current quarterly EBITDA of OCUL is -$44.33 M
What is the all time high quarterly EBITDA for Ocular Therapeutix?
Ocular Therapeutix all-time high quarterly EBITDA is $5.45 M
What is Ocular Therapeutix quarterly EBITDA year-on-year change?
Over the past year, OCUL quarterly EBITDA has changed by $0.00 (0.00%)
What is Ocular Therapeutix TTM EBITDA?
The current TTM EBITDA of OCUL is -$176.14 M
What is the all time high TTM EBITDA for Ocular Therapeutix?
Ocular Therapeutix all-time high TTM EBITDA is $2.54 M
What is Ocular Therapeutix TTM EBITDA year-on-year change?
Over the past year, OCUL TTM EBITDA has changed by $0.00 (0.00%)